Therapy of hyperthyroidism

Experimental and Clinical Endocrinology and Diabetes

Volumn 111, Issue 6, 2003, Pages 305-318

  Miehle, K ^a   Paschke, R ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Antithyroid drugs; Graves' disease; Radioiodine; Surgery; Thyroid autonomy

Indexed keywords

ALCOHOL; AMIODARONE; ANTITHYROID AGENT; CARBIMAZOLE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIOURACIL;

ADULT; AGRANULOCYTOSIS; ANOREXIA; APLASTIC ANEMIA; ARTHRALGIA; ARTHRITIS; BONE MARROW DEPRESSION; CHILD; DISEASE EXACERBATION; EUROPE; FEVER; GASTROINTESTINAL SYMPTOM; GERMANY; GRAVES DISEASE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOPROTHROMBINEMIA; HYPOTHYROIDISM; NAUSEA; NEWBORN; OBSTRUCTIVE JAUNDICE; PREGNANCY; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; REVIEW; SKIN MANIFESTATION; SMELLING DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE DISORDER; THROMBOCYTOPENIA; THYROID CRISIS; THYROIDECTOMY; THYROTOXICOSIS; TREATMENT INDICATION; URTICARIA; VASCULITIS; VOMITING;

ANTITHYROID AGENTS; CHILD; FEMALE; HUMANS; HYPERTHYROIDISM; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; SEX CHARACTERISTICS; THYROTOXICOSIS;

EID: 0141920568     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42719     Document Type: Review

References (202)

1. Anonymous. American Association of Clinical Endocrinologists releases clinical guidelines for thyroid disease. Am Fam Physician 1995; 51: 679-680
2. Adewuyi J, Sigola LB, Keogh E. African neutropaenia in Zimbabwe. Cent Afr J Med 1994; 40: 108-110
3. Administration of Radioactive Substances Advisory Committee. Notes for Guidance on the Administration of Radioactive Substances to Persons for Purposes of Diagnosis, Treatment, or Research. London: Department of Health ARSAC Secretariat, 1993
4. Alexander WD, Beckers C, Becker A, Lazarus J, Krenning E, Schlumberger, Williams D. Iodine 131 Therapy for Thyrotoxicosis towards 2000. Report of the European Thyroid Association Committee on Radio Iodine Therapy in Thyrotoxicosis. Belgium: Mallinckrodt Medical, 1995
5. Alexander WD, Evans V, Macaulay A, Gallagher TFJ, Londono J. Metabolism of 35S-labelled antithyroid drugs in man. Br Med J 1969; 2: 290-291
6. Allanic H, Fauchet R, Orgiazzi J. Antithyroid drugs and Graves' disease: a prospective randomised evaluation of the efficacy of treatment duration. J Clin Endocrinol Metab 1990; 70: 675-679
7. Andrade VA, Gross JL, Maia AL The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab 2001; 86: 3488-3493
8. Arbelle JE, Porath A. Practice guidelines for the detection and management of thyroid dysfunction. A comparative review of the recommendations. Clin Endocrinol 1999; 51: 11-18
9. Arem R. Recurrent transient thyrotoxicosis in multinodular goitre. Postgrad Med J 1990; 66: 54-56
10. Astwood EB. Chemotherapy of hyperthyroidism. Häarvey Lect (Abstract) 1945; 40: 195-235
11. Astwood EB, van der Laan WP. Thiouracil derivates of greater activity for the treatment of hyperthyroidism. J Clin Endocrinol 1945; 5: 424-430
12. Azizi F. Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter. J Clin Endocrinol Metab 1985; 61: 374-377
13. Azizi F, Khoshinat M, Bahrainian M, Hedayati M. Thyroid function and intellectual development of infants nursed by mothers taking methimazole. J Clin Endocrinol Metab 2000; 85: 3233-3238
14. Bähre M, Hilgers R, Lindemann C, Emrich D. Thyroid autonomy: sensitive detection in vivo and estimation of its functional relevance using quantified high-resolution scintigraphy. Acta Endocrinol (Copenh) 1988; 117: 145-153
15. Baltisberger BL, Minder CE, Burgi H. Decrease of incidence of toxic nodular goitre in a region of Switzerland after full correction of mild iodine deficiency. Eur J Endocrinol 1995; 132: 546-549
16. Banga JP, Harris PE. Potential pathogenicity of autoantibodies to thyrotropin receptor in treated, euthyroid patients with Graves' disease. Eur Journal Endocrinol 1998; 139: 139-142
17. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 1996; 81: 2930-2933
18. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73-78
19. Bay V, Engel U, Zornig C. Technics and complications in reinterventions on the thyroid. Wien Klin Wochenschr 1988; 100: 352-354
20. Benbassat CA, Mechlis-Frish S, Cohen M, Blum I. Amiodarone-induced thyrotoxicosis type 2: a case report and review of the literature. Am J Med Sci 2000; 320: 288-291
21. Benker G, Reinwein D, Kahaly G, Tegler L, Alexander WD, Fassbinder J, Hirche H. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol 1998; 49: 451-457
22. Benker G, Vitti P, Kahaly G, Raue F, Tegler L, Hirche H, Reinwein D. Response to methimazole in Graves' disease. The European Multicenter Study Group. Clin Endocrinol 1995; 43: 257-263
23. Buerklin EM, Schimmel M, Utiger RD. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs. J Clin Endocrinol Metab 1976; 43: 419-427
24. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131) I ablation for Graves' disease. J Clin Endocrinol Metab 2001; 86: 3016-3021
25. Chambers JBJ, Pittman CS, Suda AK. The effects of propranolol on thyroxine metabolism and triiodothyronines production in man. J Clin Pharmacol 1982; 22: 110-116
26. Chazenbalk GD, Pichurin P, McLachlan SM, Rapoport B. A direct binding assay for thyrotropin receptor autoantibodies. Thyroid 1999; 9: 1057-1061
27. Chopra IJ. A study of extrathyroidal conversion of thyroxine (T4) to 3,3'0,5-triiodothyronine (T3) in vitro. Endocrinology 1977; 101: 453-463
28. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P. Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab 1988; 67: 656-662
29. Cooper DS. Antithyroid drugs. N Engl J Med 1984; 311: 1353-1362
30. Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD (eds). Werner and Ingbar's the Thyroid. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2000: 691-715
31. Dahlberg PA, Karlsson FA, jansson R, Wide L. Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission. J Clin Endocrinol Metab 1985; 61: 1100-1104
32. Davies TF. The pathogenesis of Graves' disease. In: Braverman LE, Utiger RD (eds). Werner and Ingbar's the Thyroid. 7th ed. Philadelphia: Lippincott-Raven, 1996: 525-536
33. Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 1989; 160: 63-70
34. De Bruin TW, Croon CD, De Klerk JM, Van Isselt JW. Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome. J Intern Med 1994; 236: 507-513
35. De Bruin TWA, Bolk JH, Bussemaker JK, Stijnen T, Schreuder GMT, Devries RRP, Van Der Heide D. Graves' disease: immunological and immunogenetic indicators of relapse. Br Med J 1988; 296: 1292-1295
36. Dietlein M, Dressler J, Joseph K, Leisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O. Guidelines for radioiodine therapy (RIT) in benign thyroid diseases. Nuklearmedizin 1999: 38 (6A): 219-220
37. Dumont JE, Lamy F, Roger P, Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992; 72: 667-697
38. Duprez L, Parma J, Van Sande J, Allgeier A, Leclere,J Schvartz C, Delisle MJ, Decoulx M, Orgiazzi J, Dumont J. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994; 7: 396-401
39. Emrich D, Bähre M. Autonomy in euthyroid goitre: maladaptation to iodine deficiency. Clin Endocrinol 1978; 8: 257-265
40. Engel U, Zornig C. The necessity of intraoperative identification of the contralateral lobe in "struma uninodosa". Chirurg 1990; 61: 454-455
41. Erickson D, Gharib H, Li H, Van Heerden JA. Treatment of patients with toxic multinodular goiter. Thyroid 1998; 8: 277-282
42. Evans PM, Webster J, Evans WD, Bevan JS, Scanlon MF. Radioiodine treatment in unsuspected pregnancy. Clin Endocrinol 1998; 48: 281-283
43. Eyre-Brook IA, Talbot CH. The treatment of autonomous functioning thyroid nodules. Br J Surg 1982; 69: 577-579
44. Farwell AP, Abend SL, Huang SK, Patwardhan NA, Braverman LE. Thyroidectomy for amiodarone-induced thyrotoxicosis. JAMA 1990; 263: 1526-1528
45. Feldt-Rasmussen U, Schleusener H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J Clin Endocrinol Metab 1994; 78: 98-102
46. Ferrari C, Reschini E, Paracchi A. Treatment of the autonomous thyroid nodule: a review. Eur J Endocrinol 1996; 135: 383-390
47. Franklyn JA, Daykin J, Drolc Z, Farmer M, Sheppard MC. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol 1991; 34: 71-76
48. Franklyn JA, Wilkins MR, Wilkinson R, Ramsden DB, Sheppard MC. The effect of propranolol on circulating thyroid hormone measurements in thyrotoxic and euthyroid subjects. Acta Endocrinol 1985; 108: 351-355
49. Führer D, Mix M, Willgerodt H, Holzapfel HP, Von Petrykowski W, Wonerow P, Paschke R. Autosomal dominant nonautoimmune hyperthyroidism. Clinical features-diagnosis-therapy. Exp Clin Endocrinol Diabetes 1998; 106 (Suppl 4): S10-S15
50. Fukata S, Kuma K, Sugawara M. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid 1999; 9: 29-31
51. Geffner DL, Azukizawa M, Hershman JM. Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man. J Clin Invest 1975; 55: 224-229
52. Gemsenjäger E. The surgical treatment of autonomous nodular goiter. Prospective long-term study. Schweiz Med Wochenschr 1992; 122: 687-692
53. Gittoes NJ, Franklyn JA. Hyperthyroidism. Current treatment guidelines. Drugs 1998; 55: 543-553
54. Glinoer D, Hesch D, Lagasse R, Laurberg P. The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol Suppl 1987; 285: 3-23
55. Goolden AW, Fraser TR. Effect of pretreatment with carbimazole in patients with thyrotoxicosis subsequently treated with radioactive iodine. Br Med J 1969; 3: 443-444
56. Greer MA, Kammer H, Bouma DJ. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves' disease. N Engl J Med 1977; 297: 173-176
57. Hamburger JL. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985; 64: 1019-1024
58. Hancock LD, Tuttle RM, Lemar H, Bauman J, Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clin Endocrinol 1997; 47: 425-430
59. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, MiyamotoT, Arai M, Nagasawa T. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-953
60. Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: long-term follow-up of 434 patients. Scottish Automated Follow-Up Register Group. Clin Endocrinol 1989; 31: 209-218
61. Hegedus L, Perrild H, Poulsen LR, Andersen JR, Holm B, Schnohr P, Jensen G, Hansen JM. The determination of thyroid volume by ultrasound and its relationship to body weight, age, and sex in normal subjects. J Clin Endocrinol Metab 1983; 56: 260-263
62. Helfand M, Redfern CC. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann Intern Med 1998; 129: 144-158
63. Henderson JM, Portmann L, Van Melle G, Haller E, Ghika JA. Propranolol as an adjunct therapy for hyperthyroid tremor. Eur Neurol 1997; 37: 182-185
64. Hennemann G, Krenning EP, Sankaranarayanan K. Place of radioactive iodine in treatment of thyrotoxicosis. Lancet 1986; 1: 1369-1372
65. Herman J, Resnitzky P, Fink A. Association between thyrotoxicosis and thrombocytopenia. A case report and review of the literature. Isr J Med Sci 1978; 14: 469-475
66. Holm LE, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson UB, Hallquist A, Larsson LG. Cancer risk after iodine131 therapy for hyperthyroidism. J Natl Cancer Inst 1991; 83: 1072-1077
67. Holm LE, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med 1982; 23: 103-107
68. Holzapfel HP, Führer D, Wonerow P, Weinland G, Scherbaum WA, Paschke R. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab 1997a; 82: 4229-4233
69. Holzapfel HP, Wonerow P, Von Petrykowski W, Henschen M, Scherbaum WA, Paschke R. Sporadic congenital hyperthyroidism due to a spontaneous germline mutation in the thyrotropin receptor gene. J Clin Endocrinol Metab 1997b; 82: 3879-3884
70. Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol 2001; 54: 385-390
71. Jackson IM. Management of thyrotoxicosis. J Maine Med Assoc 1975; 66: 224-232
72. Jensen MD, Gharib H, Naessens JM, Van Heerden JA, Mayberry WE. Treatment of toxic multinodular goiter (Plummer's disease): surgery or radioiodine? World J Surg 1986; 10: 673-680
73. Kalb RE, Grossman ME. The association ofaplasia cutis congenita with therapy of maternal thyroid disease. Pediatr Dermatol 1986; 3: 327- 330
74. Kampmann J, Skovsted L. The pharmacokinetics of propylthiouracil. Acta Pharmacol Toxicol 1974; 35: 361-369
75. Kampmann JP, Hansen JM. Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet 1981; 6: 401-428
76. Kendall-Taylor P, Keir MJ, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long-term follow-up study. Br Med J (Clinical research ed.) 1984; 289: 361-363
77. Kraiem Z, Glaser B, Yigla M, Pauker J, Sadeh O, Sheinfeld M. Toxic multinodular goiter: a variant of autoimmune hyperthyroidism. J Clin Endocrinol Metab 1987a; 65: 659-664
78. Kraiem Z, Lahat N, Glaser B, Baron E, Sadeh O, Sheinfeld M. Thyrotrophin receptor blocking antibodies: incidence, characterization and invitro synthesis. Clin Endocrinol 1987b; 27: 409-421
79. Krohn K, Führer D, Holzapfel HP, Paschke R. Clonal origin of toxic thyroid nodules with constitutively activating thyrotropin receptor mutations. J Clin Endocrinol Metab 1998; 83: 130-134
80. Krohn K, Wohlgemuth S, Gerber H, Paschke R. Hot microscopic areas of iodine-deficient euthyroid goitres contain constitutively activating TSH receptor mutations. J Pathol 2000; 192: 37-42
81. Kung AW, Jones BM. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy. J Clin Endocrinol Metab 1998; 83: 514-518
82. Laurberg P, Buchholtz HP, Iversen E, Eskjaer JS, Weeke J. Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol 1986; 111: 39-43
83. Laurberg P, Nohr SB, Pedersen KM, Hreidarsson AB, Andersen S, Bulow PI, Knudsen N, Perrild H, Jorgensen T, Ovesen L. Thyroid disorders in mild iodine deficiency. Thyroid 2000; 10: 951-963
84. Laurberg P, Nygaard,B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol 1998; 139: 584-586
85. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med 1991; 229: 415-420
86. Lazarus JH. Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. Prepared by the Radioiodine Audit Subcommittee of the Royal College of Physicians Committee on Diabetes and Endocrinology, and the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond 1995; 29: 464-469
87. Lazarus JH, Marchant B, Alexander WD, Clark DH. 35-S-antithyroid drug concentration and organic binding of iodine in the human thyroid. Clin Endocrinol 1975; 4: 609-615
88. Lederbogen S, Reinwein D. Epidemiologische Daten zur thyreotoxischen Krise, eine retrospektive Untersuchung. Akt Endokrinol Stoffw 1992; 13: 62-84
89. Linos DA, Karakitsos D, Papademetriou J. Should the primary treatment of hyperthyroidism be surgical? Eur J Surg 1997; 163: 651-657
90. Lippi F, Ferrari C, Manetti L, Rago T, Santini F, Monzani F, Bellitti P Papini E, Busnardo B, Angelini F, Pinchera A. Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: results of an Italian multicenter study. The Multicenter Study Group. J Clin Endocrinol Metab 1996; 81: 3261-3264
91. LiVolsi VA. The pathology of autoimmune thyroid disease: a review. Thyroid 1994; 4: 333-339
92. Ljunggren JG, Torring O, Wallin G, Taube A, Tallstedt L, Hamberger B, Lundell G. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998; 8: 653-659
93. Lucas A, Salinas I, Rius F, Pizarro E, Granada ML, Foz M, Sanmarti A. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism? J CIin Clin Endocrinol Metab 1997; 82: 2410-2413
94. MacFarlane IA, Shalet SM, Beardwell CG, Khara JS. Transient hypothyroidism after iodine-131 treatment for thyrotoxicosis. Br Med J 1979; 2: 421
95. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J Clin Endocrinol Metab 2001; 86: 2354-2359
96. Mann K, Dralle H, Gärtner R, Grußdorf M, Grü ters-Kieslich A, Meng W, von zur Mühlen A, Reiners C. Schilddrüse. In: Deutsche Gesellschaft für Endokrinologie (ed). Rationelle Therapie in der Endokrinologie. Stuttgart, New York: Thieme Verlag, 1997: 35-102
97. Marchant B, Brownlie BE, Hart DM, Horton PW, Alexander WD. The placental transfer of propylthiouracil, methimazole and carbimazole. J Clin Endocrinol Metab 1977; 45: 1187-1193
98. Marchant B, Lees JF, Alexander WD. Antithyroid drugs. Pharmacol Ther [B] 1978; 3: 305-348
99. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Mazzi B, Rocchi R, Barbesino G, Pinchera A. Graves' ophthalmopathy and 1311 therapy. QJ Nucl Med 1999; 43: 307-312
100. Marinelli LD, Quinby EH, Hine GJ. Dosage determination with radioactive isotopes. Practical considerations in therapy and protection. AmJ Roentgenol 1948; 59: 260-281
101. Martino E, Pinchera A, Capiferri R, Macchia E, Sardano G, Bartalena L, Mazzanti F, Baschieri L Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism. J Clin Endocrinol Metab 1976; 43: 543-549
102. Masiukiewicz US, Burrow GN. Hyperthyrtoidism in pregnancy: diagnosis and treatment. Thyroid 1999; 9: 647-652
103. Maugendre D, Gatel A, Campion L, Massart C, Guilhem 1, Lorcy Y, Lescouarch J, Herry JY, Allannic H. Antithyroid drugs and Graves' disease-prospective randomized assessment of long-term treatment. Clin Endocrinol 1999; 50: 127-132
104. McGregor AM, Petersen MM, McLachlan SM, Rooke P, Smith BR, Hall R. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med 1980; 303: 302-307
105. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220-224
106. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD, BaIon HR. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med 2002; 43: 856-861
107. Melander A, Hallengren B, Rosendal-Helgesen S, Sjoberg AK, WahlinBoll E. Comparative In Vitro Effects and In Vivo Kinetics of Antithyroid Drugs. Eur J Clin Pharmacol 1980; 17: 295-299
108. Mestman JH. Hyperthyroidism in pregnancy. Clinical obstetrics and gynecology 1997; 40: 45-64
109. Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest 1994; 17: 29-36
110. Meyer-Gessner M, Benker G, Olbricht T, Windeck R, Cissewski K, Reiners C, Reinwein D. Side effects of antithyroid therapy of hyperthyroidism. A study of 1256 continuously treated patients. Dtsch Med Wochenschr 1989; 114: 166-171
111. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998; 8: 119-124
112. Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol 1994; 84: 946-949
113. Miller JM, Block MA. Functional autonomy in multinodular goitre. JAMA 1970; 214: 535-539
114. Miloni E, Studer H. Functional and morphologic particularities of the autonomous follicles in human goiters. J Mol Med (Abstract) 1980; 4: 7
115. Moll Jr GW, Patel BR. Pediatric Graves' disease: therapeutic options and experience with radioiodine at the University of Mississippi Medical Center. South Med J 1997; 90: 1017-1022
116. Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y, Mimura T. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol 1984; 20: 695-700
117. Momotani N, Yamashita R, Makino F, Noh JY, Ishikawa N, Ito K. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil. Clin Endocrinol 2000; 53: 177-181
118. Monzani F, Caraccio N, Goletti O, Lippolis PV, Casolaro A, Del Guerra P, Cavina E, Miccoli P. Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients. Clin Endocrinol 1997; 46: 9-15
119. Monzani F, Goletti O, Caraccio N, Del Guerra P, Ferdeghini M, Pucci E, Baschieri L. Percutaneous ethanol injection treatment of autonomous thyroid adenoma: hormonal and clinical evaluation. Clin Endocrinol 1992; 36: 491-497
120. Mortimer RH, Cannell GR, Addison RS, Johnson LP, Roberts MS, Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab 1997; 82: 3099-3102
121. Mortimer RH, Galligan JP, Cannell GR, Addison RS, Roberts MS. Maternal to fetal thyroxine transmission in the human term placenta is limited by inner ring deiodination. J Clin Endocrinol Metab 1996; 81: 2247-2249
122. Mujtaba Q, Burrow GN. Treatment of hyperthyroidism in pregnancy with propylthiouracil and methimazole. Obstet Gynecol 1975; 46: 282-286
123. Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J 1995; 88: 973-976
124. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Hansen BM, Soe-Jensen P, Hansen JM. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. J Intern Med 1995; 238: 491-497
125. Nygaard B, Hegedus L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol 1999; 50: 197-202
126. O'Brien T, Gharib H, Suman VJ, Van Heerden JA. Treatment of toxic solitary thyroid nodules: surgery versus radioactive iodine. Surgery 1992; 112: 1166-1170
127. Pacini F, Elisei R, Di Coscio GC, Anelli S, Macchia E, Conchetti R, Miccoli P, Arganini M, Pinchera A. Thyroid carcinoma in thyrotoxic patients treated by surgery. J Endocrinol Invest 1988; 11: 107-112
128. Page SR, Sheard CE, Herbert M, Hopton M,Jeffcoate WJ. A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol 1996; 45: 511-516
129. Palit TK, Miller CC, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: A meta-analysis. J Surg Res 2000; 90: 161-165
130. Paracchi A, Ferrari C, Livraghi T, Reschini E. Macchi RM, Bergonzi M, Raineri P. Percutaneous intranodular ethanol injection: a new treatment for autonomous thyroid adenoma. J Endocrinol Invest 1992; 15: 353-362
131. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365: 649-651
132. Parma J, Duprez L, Van Sande J, Hermans J, Rocmans P, Van Vliet G, Costagliola S, Rodien P, Dumont JE, Vassart G, Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997; 82: 2695-2701
133. Paschke R. Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Exp Clin Endocrinol Diabetes 1996; 104 Suppl 4: 129-132
134. Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. N Engl J Med 1997; 337: 1675-1681
135. Paschke R, Vogg M, Kristoferitsch R, Aktuna D, Wawschinek O, Eber O, Usadel KH. Methimazole has no dose-related effect on the intensity of the intrathyroidal autoimmune process in relapsing Graves' disease. J Clin Endocrinol Metab 1995; 80: 2470-2474
136. Pedersen OM, Aardal NP, Larssen TB, Varhaug JE, Myking O, Vik-Mo H. The value of ultrasonography in predicting autoimmune thyroid disease. Thyroid 2000; 10: 251-259
137. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyriodism: Standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995; 25: 186-193
138. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. Eur J Clin Invest 1996; 26: 59-63
139. Pomorski L, Cywinski J, Rybinski K. Cancer in hyperthyroidism. Neoplasma 1996; 43: 217-219
140. Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998; 19: 673-716
141. Reeves RA, From GL, Paul W, Leenen FH. Nadolol, propranolol, and thyroid hormones: evidence for a membrane-stabilizing action of propranolol. Clin Pharmacol Ther 1985; 37: 157-161
142. Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, Krause TM. Radioiodine therapy in Graves' disease based on tissueabsorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging 2002; 29: 1118-1124
143. Reinwein D, Benker G, König MP, Pinchera A, Schatz H, Schleusener H. Hyperthyroidism in Europe: clinical and laboratory data of a prospective multicentric study. J Endocrinol Invest 1986; 9 (Suppl 2): 1-36
144. Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab 1993; 76: 1516-1521
145. Reschini E, Peracchi M. Thyroid scintigraphy during antithyroid treatment for autonomous nodules as a means of imaging extranodular tissue. Clin Nucl Med 1993; 18: 597-600
146. Rittmaster RS, Abbott EC, Douglas R, Givner ML, Lehmann L, Reddy S, Salisbury SR, Shlossberg AH, Tan MH, York SE. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. J Clin Endocrinol Metab 1998; 83: 814-818
147. Rivkees SA, Sklar C, Freemark M. The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998; 83: 3767-3776
148. Rojdmark J, Jarhult J. High long term recurrence rate after subtotal thyroidectomy for nodular goitre. Eur J Surg 1995; 161: 725-727
149. Romaldini JH, Bromberg N, Werner RS, Tanaka LM, Rodrigues HF, Werner MC, Farah CS, Reis LC. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab 1983; 57: 563-570
150. Ron E, Doody MM, Becker DV. Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998; 280: 347-355
151. Roti E, Montermini M, Roti S, Gardini E, Robuschi G, Minelli R, Salvi M, Bentivoglio M, Guiducci U, Braverman LE. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients. Arch Intern Med 1988: 148: 1919-1921
152. Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyroid 2001; 11: 493-500
153. Rypance GW, Woods CD, Donnelly M, Oliver J, Alexander W. Carbimazole and breast feeding (Letter). Lancet 1987; 1: 928
154. Sabri O, Zimni M, Schreckenberger M, Reinartz P, Ostwald E, Buell U. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy. Thyroid 1999; 9: 1181-1188
155. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease [published erratum appears in Acta Endocrinol (Copenh) 1989 Aug; 121 (2): 304]. Acta Endocrinol 1989; 120: 689-701
156. Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr WR. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease [published erratum appears in Acta Endocrinol (Copenh) 1989 Aug; 121 (2): 304]. Acta Endocrinol 1989; 120: 689-701
157. Scholz GH, Hagemann E, Arkenau C, Engelmann L, Lamesch P, Schreiter D, Schonfelder M, Olthoff D, Pascke R. Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure? Thyroid 2003; in press
158. Schwab KO, Sohlemann P, Gerlich M, Broecker M, Petrykowski W, Holzapfel HP, Paschke R, Gruters A, Derwahl M. Mutations of the TSH receptor as cause of congenital hyperthyroidism. Exp Clin Endocrinol Diabetes 1996; 104 (Suppl 4): 124-128
159. Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years? J Nucl Med 1993; 34: 1638-1641
160. Shoenfeld Y, Alkan ML, Asaly A, Carmeli Y, Katz M. Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 1988; 41: 273-277
161. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997; 7: 755-760
162. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995; 273: 808-812
163. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990; 70: 1518-1524
164. Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ. Longterm follow-up study of compensated low-dose 1311 therapy for Graves' disease. N Engl J Med 1984: 311: 426-432
165. Stanbury JB, Ermans AE, Bourdoux P, Todd C, Oken E, Tonglet R, Vidor G, Braverman LE, Medeiros-Neto G. Iodine-induced hyperthyroidism: occurrence and epidemiology. Thyroid 1998; 8: 83-100
166. Stanley MM, Astwood EB. 1-methyl-2-mercaptoimidazole: an antithyroid compound highly active in man. Endocrinology 1949; 44: 588-589
167. Studer H, Peter HJ, Gerber H. Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth. Endocr Rev 1989; 10: 125-135
168. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150: 621-624
169. Takamatsu J, Kuma K, Mozai T. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease. J Clin Endocrinol Metab 1986; 62: 980-983
170. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326: 1733-1738
171. Taurog A. The mechanism of action of the thioureylene antithyroid drugs. Endocrinology 1976; 98: 1031-1046
172. Taurog A, Dorris ML. A reexamination of the proposed inactivation of thyroid peroxidase in the rat thyroid by propylthiouracil. Endocrinology 1989; 124: 3038-3042
173. Trülzsch B, Krohn K, Wonerow P, Chey S, Holzapfel HP, Ackermann F,
174. Tunbridge WM, Evered DC, Hall R. Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol 1977; 7: 481-493
175. Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995; 5: 243-247
176. Van Dijke CP, Heydendael RJ, De Kleine MJ. Methimazole, carbimazole, and congenital skin defects. Ann Intern Med 1987; 106: 60-61
177. Vanderpump MP, Ahlquist JA, Franklyn JA, Clayton RN. Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. Br Med J 1996; 313: 539-544
178. Vassart G, Dumont JE. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992; 13: 596-611
179. Velkeniers B, Cytryn R, Vanhaelst L, Jonckheer MH. Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered. Lancet 1988; 1: 1127-1129
180. Vitti P. Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease. Eur J Endocrinol 2000; 142: 22-24
181. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7: 369-375
182. Volpe R. Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid 1994; 4: 217-223
183. Wahl RA, Rimpl 1, Saalabian S, Schabram J. Differentiated operative therapy of thyroid autonomy (Plummer's disease). Exp Clin Endocrinol Diabetes 1998; 106 (Suppl 4): S78-S84
184. Wallaschofski H, Kaczmarek M, Miehle K, Hentschel B, Paschke R. Differences between thyrotropin receptor antibody bioactivity and inhibition of 125I-bovine thyrotropin binding. Thyroid 2000; 10: 897-907
185. Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment. Horm Metab Res 2002; 34: 383-388
186. Wallaschofski H, Orda C, Führer D, Holzapfel HP, Krohn K, Miehle K, Neumann S, Georgi P, Paschke R. Distinction between autoimmune and nonautoimmune hyperthyroidism by determination of thyrotropin-receptor antibodies in patients with the scintigraphic diagnosis of disseminated autonomy. Thyroid 2001 a; 11: 710-711
187. Wallaschofski H, Orda C, Georgi P, Miehle K, Paschke R. Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter. Horm Metab Res 2001 b; 33: 504-507
188. Wallaschofski H, Paschke R. Detection of thyroid stimulating (TSAB)and thyrotropin stimulation blocking (TSBAB) antibodies with CHO cell lines expressing different TSH-receptor numbers. Clin Endocrinol 1999; 50: 365-372
189. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991; 1: 129-135
190. Weber C, Scholz GH, Lamesch P, Paschke R. Thyroidectomy in iodine induced thyrotoxic storm. Exp Clin Endocrinol Diabetes 1999; 107: 468-472
191. Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-1248
192. Weetman AP, McGregor AM, Hall R. Evidence for an effect of antithyroid drugs on the natural history of Graves' disease. Clin Endocrinol 1984; 21: 163-172
193. Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. QJ Med 1994; 87: 337-341
194. Weiss I, Davies TF. Inhibition of immunoglobulin -secreting cells by antithyroid drugs. J Clin Endocrinol Metab 1981; 53: 1223-1228
195. Werner RS, Romaldini JH, Farah CS, Werner MC, Bromberg N. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease. Thyroid 1991; 1: 293-299
196. Witte J, Goretzki PE, Dotzenrath C, Simon D, Felis P, Neubauer M, Roher HD. Surgery for Graves' disease: total versus subtotal thyroidectomy - results of a prospective randomized trial. World J Surg 2000; 24: 1303-1311
197. Worthington J, Byfield PG, Himsworth RL Heterogeneity of circulating TSH-receptor antibodies in thyroid disease demonstrated directly by chromatography. Clin Endocrinol 1991; 34: 147-154
198. Yamada T, Koizumi Y, Sato A, Hashizume K, Aizawa T, Takasu N, Nagata H. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease. J Clin Endocrinol Metab 1984; 58: 676-680
199. Yamada T, Takasu N, Sato A, Aizawa T, Koizumi Y. Pituitary-thyroid feedback regulation in patients with Graves' disease during antithyroid drug therapy. J Clin Endocrinol Metab 1982; 54: 83-88
200. Young RJ, Sherwood MB, Simpson JG, Nicol AG, Michie W, Beck JS. Histometry of lymphoid infiltrate in the thyroid of primary thyrotoxicosis patients. Relation of extent of thyroiditis to preoperative drug treatment and postoperative hypothyroidism. J Clin Pathol 1976; 29: 398-402
201. Zanella E, Rulli F, Muzi M, Sianesi M, Danese D, Sciacchitano S, Pontecorvi A. Prevalence of thyroid cancer in hyperthyroid patients treated by surgery. World J Surg 1998; 22: 473-477
202. Zhu Y, Portmann L, Denereaz N, Lemarchand-Beraud T. Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases. Eur J Endocrinol 1994; 131: 359-368